New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
07:32 EDTLGNDLigand says Phase 3 PETIT2 study met primary endpoint
Ligand Pharmaceuticals (LGND) announces that its partner, GlaxoSmithKline (GSK), presented the results from the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in pediatric patients with chronic immune thrombocytopenic purpura. Eltrombopag - marketed as Promacta in the U.S. and as Revolade in Europe and other countries across the world - met its primary endpoint, achieving a statistically significant improvement in platelet counts with almost 40% of patients treated with eltrombopag attaining a consistent platelet response for 6 of 8 weeks compared to placebo. The PETIT2 study results were highlighted today as part of a Press Briefing and Oral Presentation at the European Hematology Association Annual Congress in Milan, Italy. GSK also announced that it is moving forward with planned regulatory submissions for a pediatric indication in cITP later this year. Efficacy results for PETIT2 were consistent across age cohorts. The safety profile was consistent with the established profile for eltrombopag and no new safety concerns were observed. The most common adverse events occurring most frequently in the eltrombopag arm included nasopharyngitis, rhinitis, cough and respiratory tract infection. Grade 3/4 AEs occurred in 12.7% of patients treated with eltrombopag and 10.3% of patients in the placebo group. Serious AEs were reported in 8% of eltrombopag-treated patients vs. 14% in the placebo arm. Additional results from an early phase study of eltrombopag in previously treated pediatric patients with cITP were also presented at the European Hematology Association Annual Congress.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:28 EDTLGNDLigand sees 2015 revenue $81M-$83M, consensus $91.87M
Three estimates make up consensus. Guidance issued in analyst day presentation slides.
10:27 EDTLGNDLigand sees 2017 EPS above $4.65, revenue above $146M
Subscribe for More Information
10:27 EDTLGNDLigand sees 2016 EPS above $3.20, revenue above $107M
Subscribe for More Information
10:25 EDTLGNDLigand guides 2015 EPS $2.14-$2.18, consensus $2.42
Subscribe for More Information
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link
November 12, 2014
09:16 EDTLGNDLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use